Alternate Careers for PhDs: So You Think You Want to Be a Consultant?
Over the past year or so, more graduate students and postdoctoral fellows have been asking me about management consulting careers in the life sciences. I spent several years working as an independent management consultant and while it was a great experience the revenue stream was unreliable at best and the ability to work was highly contingent upon the economy. However, I can assure that my experiences as an independent management consultant were marketing different than those of consultants who work at the consulting firms like McKinsey or the Boston Consulting Group. For those of you interested in life style of a high-powered management consultant I highly recommend you visit their websites for more info.
I invited Susan Colilla, PhD, MPH, President of the consulting firm Integrative Epidemiology LLC describe her experiences about becoming a life sciences consultant so that BioJobBlog job readers (who may be considering this as a career option), might get an idea and appreciate what it takes to get into and be successful in this line of work.
My Life as a Life Sciences Management Consultant
by Susan Colilla
After doing a second postdoc at University of Pennsylvania as an Instructor (nebulous junior non-faculty type position) and becoming frustrated with all the extensive work requirements for a tenure-track position, I started searching for a job in pharmaceutical industry.
While searching for a position, a potential employer, who didn’t have an opening at the time, asked if I would be interested in consulting. As I was interested in this area, I started consulting for industry and realized that I enjoyed working on different projects in epidemiology and genetics, and loved that I could work from my home office and give up a commute.
The flexibility in consulting is great. I plan the work around my schedule, and the pay has been rewarding as well. Last year, I formally incorporated my business, Integrative Epidemiology, LLC. I offer services in literature reviews, study planning/design, data analysis and grant or manuscript writing in the areas of human genetics or epidemiology.
As I build my business, I have learned about how to run a business, bookkeeping/billing, taxes, legal issues/contracts, and marketing. Moving from academia to pharma/industry is tricky unless you have connections with those who hire in the industry. One of the biggest challenges for me as a self-employed consultant is dedicating a good proportion of my time to networking with others and marketing my services, rather than doing science-related work. It helps that I am very social by nature and enjoy meeting new people.
I am also fortunate to be married to someone who makes a good income and receives benefits as this helps support our family. There can be a sporadic flow of income with consulting, especially during a recession and new business slows down. I have also partnered up with another consulting group (Venebio, LLC, based in Richmond, VA) to expand the pool of potential clients and work with a group of scientists to offer a broader range of services.
For those of you who want to learn more about getting into the consultant business, Susan highly recommends an article that recently appeared in the Scientist. She shared with me that the article offers a great list of things to consider before starting a consultancy and that she “wished that she had seen it a couple years ago when I started out in this business!”
Until next time...
Good Luck and Good Job Hunting!!!!
I suspect by the growing numbers of people who read BioJobBlog, that some of you may be beginning to wonder who I am. While nobody has taken me to task about my credentials or musings to date, I figured it may be worthwhile to share my “story” with those BioJobBlog readers who may be at a crossroads in their careers. I credit my graduate school experiences and PhD degree for the tenacity, perseverance and the ability to reinvent myself during an eclectic, and oft times, circuitous career path. 
I received a call today from GDS International, a UK-based b2b publishing company, alerting me to its annual, event called the 
Whenever I do resume critiquing at scientific meetings, someone always asks about how to negotiate a job offer. Most of the people that ask the question aren't even close to receiving a job offer and I do my best to deflect the question. However, at a recent meeting, I spent 30 minutes with a PhD student who had received an offer advising him on how to get a better deal from his prospective new employer. This got me thinking and I invited Joe Tringali, a veteran recruiter with lots of negotiating experience to write a blog post about strategies and things to consider when negotiating a job offer..jpg)
The
I don’t want to brag but I have been touting career options in health informatics and health information technology (HIT) for the past year or so. Today, I came across a post by CareerBuilders declaring health informatics and HIT are the hottest new career trends to hit the market in recent years. As the drive towards digitizing medical and healthcare records continue, there will be literally thousands of job opportunities for people with the right skill set. This is what the post had to say about health informatics and HIT careers and job opportunities. .jpg)
An annual survey conducted by Science magazine and the American Association has identified the 
In a previous post I 
I came across a .png)
For the first time in history, more people are searching the Internet for health information than asking doctors. Web 2.0 and social media tools are allowing people to discover new ways to connect, learn and engage one other in search of healthcare and drug information.(2).jpg)
There was an interesting .jpg)
There has been a growing reliance on the use of online tools to teach science to primary, secondary and college students. This makes sense because anybody who has pursued a science career will tell you that using web-based programs, applications and searches is absolutely essential when conducting scientific research. To that end, Amber Johnson at 
The Belgian chemical manufacturer Solvay 
(3).jpg)
Mark Senak at the.jpg)
I previously posted an 
Mark Senak who runs the.jpg)
Twitter is arguably the hottest new platform to hit the social media scene is the past five years. Twitter devotees are convinced that anything is possible if the microblogging platform is used correctly. In today’s economy, the most pressing need for many people is finding a job. While Twitter is effective for branding, marketing and occasionally some witty intellectual exchanges, its usefulness for jobseekers has yet to be demonstrated. To that end, there was a recent instructional case study on TwiTip—.gif)
Under ideal circumstances, job interviews can be very stressful and emotionally draining. After all, how you perform on a job interview will likely determine whether or not you get an offer for a position. Unfortunately, unless you are an experienced jobseeker, who has has participated in many job interviews, you will likely be taken by surprise at your next one. To that end, the following tips, when adhered to, will likely help to reduce your stress level at your next job interview and possibly increase your chances of getting a job offer..jpg)
Pharmaceutical sales representatives, along with R&D scientists have been the largest casualties of recent downsizing that has been sweeping the life sciences industry. Increasing regulatory scrutiny, decreasing numbers of new drug approvals and an increasing reliance on e-based technologies to sell drugs have almost rendered the traditional pharma rep obsolete. .png)
During my recent trip to Vermont and Woodstock, NY I had several conversations about Twitter. Surprisingly, I was being asked to explain Twitter to my nephews, both of whom are in their early 20s and to family friends who are in their late 40s and beyond. Also, at several recent science career fairs that I attended many graduate students and postdocs had never heard of Twitter or it they had, they don’t use it. Initially, this was puzzling but after considering the most recent Twitterverse demographics –I think the average age of Twitter users is around 35 to 40—it made more sense to me..gif)
Eli Lilly & Co. is .jpg)
Pharmaceutical,biotechnology and other companies that sell prescription drugs and devices are deathly afraid of adverse events (AEs) associated with their products. For those of you who may not know, companies with approved prescription drugs and medical devices are required to track and report any adverse events associated with their products to regulatory agencies like the US Food and Drug Administration (FDA). If FDA receives enough AE complaints about a product, the agency will investigate to determine whether or not there may be efficacy, safety or tolerability issues with it. And, if FDA thinks that the AEs are legitimate, it may ask a company to conduct Phase IV clinical trials with the product in question or require that changes be made to the product’s label. Not surprisingly, these outcomes can be time consuming and perhaps more importantly, costly. Label changes—especially for blockbuster products—frequently lead to changes in physician prescribing habits which can translate into a loss of revenue. Despite the fact that ALL drugs exhibit AEs, many companies falsely cling to the hope that there will be few, if any, AEs reported for their products.
Several weeks ago, I 
Despite dire predictions, the biotechnology industry appears to be weathering the recession better than most. According to a
Back in the late 1990s, applying for jobs online was all the rage! The technology was new and fresh and applying for jobs online was fast and easy. Companies raced to build corporate websites for prospective job applicants, major job boards like Monster and Careerbuilder were launched and human resources professionals though they were ushering in a “new era of employee recruitment and retention.” While applying for jobs online once seemed like a panacea for both job seekers and corporate employers, it never has lived up to all the fanfare and hype!
It’s no secret that major pharmaceutical companies are 
Despite its humble beginnings in the late 1970s, the biotechnology industry has transformed itself into one of the most vibrant sectors of the American economy. Pharmaceutical companies, once the bell weather of the life sciences industry, have finally conceded that biotechnology and not small molecules are the industry’s future!.jpg)
Amber Johnson at 
Mark Senak, who writes the outstanding .jpg)
Word on the street suggests that Roche has severed its relationship with the Pharmaceutical Manufacturers of America (PhRMA) the trade group that represents and lobbies on behalf of the pharmaceutical industry. The recent purchase of Genentech must have convinced the venerable 100 year old pharmaceutical company that proteins not small molecule drugs are the key to its future.
While life sciences companies are still reluctant to take the “social media plunge,” many other companies (with active social media programs) frequently hire employees known as social media managers who oversee and run their social networks. This is because successful social media websites require daily attention and are extremely time consuming and labor intensive. In general, employees who are hired for these jobs have strong backgrounds in social media and technology but frequently possess little expertise in the industry that they are working in. Because social media is so new, many hiring managers believe that the social media and technology skills of these managers are more important than an understanding of the industry that they work in. However, while this practice may be acceptable in other industries, it won’t be the case for the social media managers who oversee pharmaceutical, biotechnology and medical devices and diagnostics social media websites. These managers will likely be required to have a firm understanding of current rules and regulations guiding drug development and marketing and advertising of approved life sciences products. This will be necessary if the drug makers who hire these managers want to steer clear of regulatory scrutiny by the US Food and Drug Administration and other regulatory agencies.
For those of you interested in the Canadian biotechnology scene I want to mention a good resource that I came across recently. The Canadian BioTechnologist 2.0 Blog (.jpg)
As many of you may know, I attend national science meetings where I offer resume critiquing services and give career development seminars on topics ranging from resume writing to alternate career opportunities for life scientists. Frequently, I critique the resumes of 
Yesterday, I gave a lecture entitled “Alternate Careers: Taking the Road Less Traveled” to over 100 members of the University of Pennsylvania’s Biomedical Graduate Student Association. As always, there were many good questions and comments during and after the presentation. Some of the career anecdotes offered by several of the students reminded me of a conversation that I had several weeks ago with one of my Fundamentals of Bioscience students—I teach a Product Development and Regulatory Affairs course in the program—who refreshed my memory about a typical graduate student approach to career development and job searching. “We don’t think about jobs or our careers until we begin writing our PhD theses” she said. “Until then, our advisers don’t talk about careers or jobs and only bring it up because our funding will run out” she added. Admittedly, I had forgotten this because so many years have passed since my graduate student days. That said, it forced me to consider how much the life sciences job market has changed since I was graduate student and how vitally important it is for today’s graduate students to think about and possibly explore different career options throughout the course of their graduate training.
Carl Icahn, former corporate raider, hedge fund owner and activist investor, is still trying to exert his influence at Biogen/IDEC a biotechnology company in which he owns 5.6 percent of its outstanding shares of stock. .jpeg)
After months of complaints by university officials and scientific organizations, the US State Department .jpg)
By now, I think that most BioJobBlog readers understand that the job market for life scientists is lousy and that it isn’t likely to improve anytime soon. I know that many of you have spent close to 10 years training for a shot at an R&D job but the reality is that everybody needs to work to put food on the table—whether or not you find a job in your chosen profession. To that end, now may be a good time for those of you who are finding it difficult to land a job to consider one more year of training to get a certificate in a field that keeps you in science but not in R&D..gif)
Over the past three years, more than
The National Institutes of Health (NIH) announced on Wednesday that it was creating a new program aimed at “finding treatments for some of the 6,800 rare diseases that collectively affect about 25 million Americans.” 
Medtronics, the world's largest medical-device company, (1).jpg)
There has been no shortage of conversation lately about current problems facing the pharmaceutical and biotechnology industries. These industries are faced with the effects of the global recession because of a dangerous combination of falling revenues and spiraling costs. Life sciences company executives are looking for ways to cut production costs and cope with the current decline in drug sales.(1).jpg)
Roche announced Tuesday that it will replace Arthur Levinson, PhD, Genentech’s current CEO and American biotechnology pioneer, with Pacal Soriot, DVM, MBA who currently leads Roche’s worldwide commercial operations. Dr. Levinson will become Chairman of Genentech’s newly configured board of directors but no longer have control over day-to-day operations at the company. Mr. Soriot will become CEO of Genentech and head all of Roche’s pharmaceutical activities in the US. Some of the other changes that will occur at the company include: Susan Desmond-Hellmann, Genentech’s president of product development, will move into an advisory role after the middle of this year. Genentech CFO David Ebersman is leaving the company and Ian Clark, who heads commercial operations for Genentech, will be chief marketing officer of Roche’s pharma division..jpg)
Are you a life sciences or healthcare professional with a passion for computers, IT or software development? If so, you might want to consider a career in health informatics—one of the hottest, new fields in the life sciences and healthcare industries. Health informatics specialists typically have expertise in medical records and claims, clinical care and programming. In other words, they have a foot in two worlds— medicine and technology — and can easily bridge the often daunting gap between them. It is important to point out that there is a difference between healthcare IT and informatics personnel. The health IT people run the servers and install software, but the informatics people are the ones who analyze and interpret clinical/ medical information and work with clinical and other healthcare staff to advise and help them..jpg)
Earlier this week, the US Food and Drug Administration (FDA) sent 
Using Facebook and Twitter to find jobs is becoming routine in many industries including healthcare. However, the life sciences industry is lagging behind most others when it comes to social media and recruitment. Nevertheless, many companies and academic institutions are beginning to realize that Facebook (FB), Twitter and other science social networks are good source of qualified candidates for those difficult-to fill job openings. 
Since 2007, approximately 80,000 pharmaceutical jobs have been eliminated. The recent consolidation in the industry, e.g., Merck-Schering, Pfizer-Wyeth and Roche-Genentech suggests that many more life sciences jobs will be lost over the next year or so. Typically, to avoid law suits and possible discrimination claims, most companies will layoff a mixture of experienced and entry level employees that cover the racial, religious and age spectra. For those of you who may not know, Americans who are 40 and older constitute a “protected class of employees.” In other words, companies that layoff employees cannot disproportionately give pink slips to employees 40 years of age or older. This law was enacted because older employees typically have higher salaries and have accrued more benefits and vacation time than their more junior counterparts and eliminating them can drastically cut costs. While most companies are careful to layoff a mixture of junior and senior employees during large layoffs, a quick perusal of the demographics of employees who lose their jobs reveals that many of them are older, more experienced workers. Sacrificing a few entry level employees (to prevent any red flags) is worth it to the accountants who charged with cutting costs and orchestrating large corporate layoffs.
The US economy has lost about 7.1 million jobs since December 2007 and nationwide unemployment is hovering around 8.5 percent. Despite the lost of about 80,000 pharmaceutical jobs over the past three years and unprecedented consolidation taking place in the life sciences sector—Merck-Schering Plough, Pfizer-Wyeth and Roche-Genentech—the job prospects for scientists at biotech companies, medical devices and diagnostics, and government appear to be stronger than anticipated. While drug discovery and sales jobs may be scare, there are rapidly emerging opportunities in the fields of medical communications, regulatory affairs, biomanufacturing, clinical trials management , bioengineering, medical devices/diagnostics and website development and management..jpg)
Previously, the US Congress proposed legislation to create a regulatory approval process to allow the Food and Drug Administration (FDA) to approve generic versions of blockbuster biotechnology drugs known as follow-on biologics (FOBs). While a regulatory pathway exists for approval of generic versions of small molecule drugs (as outlined in the .jpg)
It’s official! Roche has secured more than 96 percent of shares in Genentech Inc, completing its $46.8 billion buyout of the U.S. biotech group. It now holds some 93 percent of outstanding Genentech shares, a further 3 percent are guaranteed to be delivered within the next three business days and it will integrate the U.S. biotech group as soon as possible.
As many of you know, the life sciences industry, one of the most highly regulated industries of the economy has been hesitant and reluctant to embrace social media to reach out to patients, physicians and the lay public. This is because the US Food and Drug Administration, specifically Division for Drug Marketing, Advertising and Communications (
As you all know by now, .jpg)
Merck announced today that it was buying Schering Plough, the Kenilworth-New Jersey based drug maker, for $41.1 billion. The deal comes only six weeks after Pfizer said that it would purchase NJ-based Wyeth Pharmaceuticals. Superficially, the deal may make sense for the two struggling drug makers—they co-market the cholesterol-lowering drug Vytorin and also have collaborations in the respiratory diseases area. Also, Schering Plough has the European rights to the anti-arthritis drug Remicade and its 2007 purchase of the Dutch biopharmaceutical company Organon Biosciences NV provides access to several potential biotechnology drugs. Nevertheless, the impending merger will ultimately result in job losses and higher unemployment in the state of New Jersey..jpg)
Facebook contends that it has over 175 million members, making it the largest social network in the world! Interestingly, according to an .jpg)
A panel of eight judges at the Wharton School of Business at the University of Pennsylvania was asked to identify the top 20 life-altering technologies that were developed over the last 30 years. The .jpg)
For the past decade or so, I have worked as a career counselor at national scientific meetings where I present seminars about resume writing, interviewing techniques and other career related issues. About two years ago, I started to hear about the fierce competition for H-1 and J-1 visas that foreign students must obtain to remain in the US to continue their studies and research. Many of the foreign students that I talked with sounded more like immigration lawyers than graduate students or postdocs—I was amazed at how well informed they were about visa availability and the changes and loopholes in US immigration law that can be exploited to obtain visas..jpg)
Over the past ten years or so, pundits have been warning that the US is losing its competitive edge and that it is no longer the world’s leading nation when it comes to innovation in science and technology. Measuring national competitiveness and innovation is very tricky business and until now, most of evidence to support these claims has been anecdotal. According to an .gif)
I have been accumulating anecdotal information about companies,organizations and institutions that use social media tools like Facebook, Twitter YouTube etc. I decided to attempt to conduct an informal survey to determine whether or not the life sciences sector is adopting and embracing social media to meet its objectives (whatever they may be). .jpg)
Twitter, the microblogging platform, is the current rage in social media. According to 
In the February issue of .jpg)
The 
Earlier this month, Vincent Racaniello and I launched a new social network called 
Pfizer is the largest pharmaceutical company in the world. It was able to garner that distinction by going on a decade-long buying spree that began in the mid 1990s. To date, Pfizer has acquired Warner Lambert, Pharmacia and a host of smaller specialty pharmaceutical and biotechnology companies. Despite these acquisitions, which yielded top selling blockbuster drugs like Lipitor and Celebrex, Pfizer’s stock has never performed up to analyst’s expectations. In fact, while it’s smaller and more nimble pharmaceutical competitor’s stock prices were soaring, Pfizer’s stock price was either flat or falling. While conventional wisdoms suggest that “bigger is always better” this has proven not to be the case when companies, like Pfizer, attempt to win greater market share through mergers and acquisition and also loss sight of their core business.
Did you know that the top ten pharmaceutical companies in the world spent close to $50 billion dollars last year on R&D? That sum could be used to purchase the entire US biotechnology industry except for the five largest companies—Genentech, Amgen, Gilead Genzyme and Celgene. Further, pharma’s R&D budget is about 4 times the R&D budget of all of the US biotechnology companies combined. According to a
.jpg)
Today is a sad day in the pharmaceutical and biotechnology blogging world. Pharmalot, a two year old, pioneering blog created by the intrepid Ed Silverman and the Star Ledger News has decided to call it quits. Unfortunately, the Star Ledger is in dire financial straits and it could no longer provide Ed with the support he needed to continue to run the Pharmalot blog. Please read .jpg){kind=small}
.jpg)
Glassdoor.com a site that allows people to rate CEO and company performance selected .jpg)
Like it or not, the best way to land a new job whether or not there is a recession is to network. While career counselors and recruiters trumpet the virtues of networking to job seekers, many people really don't understand what it is or how to do it correctly. I found an.jpg)
I know this is kind of odd, but I have recently begun to wonder which life sciences companies have layed off the most employees this past year. Well, for those of you out there who were also wondering we don't have to wonder any longer because Ed Silverman over at the Pharmalot blog has conveniently compiled a 
It seems that every day a new American industry asks the US government for a bailout because of impending financial exigency. That said, I was somewhat surprised to learn today that the.jpg)
I first thought about starting a social network for life sciences professionals about a year ago after joined I Facebook and LinkedIn and then learned about SciLink, one of the first social networks for scientists. Apparently, others had the same idea and today, there are currently, by my reckoning, no fewer than 20 social networks for scientists—each promoting a unique approach to networking for scientists..jpg)
The other day I was chatting with .jpg)
I want to let my readers know that a beta-version of .jpg)
.jpg)
The